Browsing by Author "Pineda, Estela"

Sort by: Order: Results:

  • A comparison of RNA-Seq results from paired formalin-fixed paraffin-embedded and fresh-frozen glioblastoma tissue samples
    Esteve-Codina, Anna; Arpí Llucià, Oriol; Martínez-García, Maria; Pineda, Estela; Mallo, Mar; Gut, Marta; Carrato, Cristina; Rovira Guerín, Ana; Lopez, Raquel; Tortosa, Avelina; Dabad, Marc; del Barco, Sonia; Heath, Simon; Bagué, Silvia; Ribalta, Teresa; Alameda Quitllet, Francisco; de la Iglesia, Nuria; Balaña, Carmen; GLIOCAT Group (Public Library of Science (PLoS), 2017)
    The molecular classification of glioblastoma (GBM) based on gene expression might better explain outcome and response to treatment than clinical factors. Whole transcriptome sequencing using next-generation sequencing ...
  • In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma
    Hernandez, Ainhoa; Muñoz-Mármol, Ana M.; Esteve-Codina, Anna; Alameda Quitllet, Francisco; Carrato, Cristina; Pineda, Estela; Arpí Llucià, Oriol; Martinez-García, Maria; Mallo, Mar; Gut, Marta; Barco Berrón, Sonia del; Gallego, Oscar; Dabad, Marc; Mesia, Carlos; Bellosillo Paricio, Beatriz; Domenech, Marta; Vidal, Noemí; Aldecoa, Iban; Iglesia, Nuria de la; Balana, Carmen (Nature Research, 2022)
    RNA-Sequencing (RNA-Seq) can identify gene fusions in tumors, but not all these fusions have functional consequences. Using multiple data bases, we have performed an in silico analysis of fusions detected by RNA-Seq in ...
  • Safety and efficacy of crizotinib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: phase Ib GEINO 1402 trial
    Martínez-García, Maria; Velasco, Guillermo; Pineda, Estela; Gil-Gil, Miguel J.; Alameda Quitllet, Francisco; Capellades Font, Jaume; Martín-Soberón, Mari Cruz; López-Valero, Israel; Tovar Ambel, Elena; Foro Arnalot, Palmira; Taus García, Álvaro; Arumí Uría, Montserrat; Hernández-Laín, Aurelio; Sepúlveda-Sánchez, Juan Manuel (MDPI, 2022)
    Background: MET-signaling and midkine (ALK ligand) promote glioma cell maintenance and resistance against anticancer therapies. ALK and c-MET inhibition with crizotinib have a preclinical therapeutic rationale to be tested ...